Hope for infants: new drug trial targets devastating seizures in rare genetic disorder
Disease control
Not yet recruiting
This study is testing whether adding a new medicine called ganaxolone to a child's current seizure medications can better control seizures in infants with a rare genetic disorder called CDKL5 deficiency. It will involve about 20 infants aged 6 months to under 2 years old. For 12 …
Phase: PHASE3 • Sponsor: Immedica Pharma AB • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC